About Us

Leadership Team

Jordi Mata-Fink, Ph.D.

Chief Executive Officer

Co-Founder

Bio

Jordi Mata-Fink is Co-founder and Chief Executive Officer at Gate Bioscience. Prior to Gate, Jordi worked at Flagship Pioneering where he helped found and launch multiple biotechnology companies, including Editas Medicine, Rubius Therapeutics, and Generate Biomedicines. Jordi trained in Chemical Engineering at Stanford and MIT. When he’s not leading Gate, Jordi is an avid youth soccer coach.

Pat Sharp, Ph.D.

VP of Discovery Sciences

Scientific Co-Founder

Bio

Pat Sharp is Scientific Co-founder and Vice President of Discovery Science at Gate. Pat was the first to demonstrate that small molecules can selectively inhibit protein secretion through Sec61 in the secretory translocon. Prior to Gate, Pat was a medicinal chemist at Merck and trained in chemical biology at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Australia and at UCSF. In addition to his scientific pursuits, Pat is an accomplished artist in multiple media, including hyper-realistic line drawing and painting.

Raman Talwar, M.S.

Chief Technology Officer

Co-Founder

Bio

Raman Talwar is Co-Founder and Chief Technology Officer at Gate. Raman is a serial entrepreneur and technology builder who has founded and contributed to innovative companies across industries including: Applied Materials, Bluestar Genomics, Third Rock Ventures, and Maze Therapeutics. Raman trained in physics and engineering and is a halfway decent ultimate frisbee player.

Brian Cathers, Ph.D.

Chief Scientific Officer

Bio

Brian is the Chief Scientific Officer at Gate, where he oversees all drug discovery activities. Prior to Gate, Brian was the CSO at Global Blood Therapeutics (GBT), acquired by Pfizer, developing drugs for sickle cell anemia. Earlier in his career, Brian led the teams at Celgene that uncovered the molecular mechanism of thalidomide and the IMiDs, ushering in the era of targeted protein degradation and producing five new investigational drugs. Brian holds a B.S. in chemistry from Emporia State University and an M.S. and a Ph.D. in medicinal chemistry from the University of Kansas.

Nina Oberbeck, Ph.D.

Director, Preclinical Translation

Bio

Nina Oberbeck is Director of Preclinical Translation at Gate Bioscience, where she leads Gate’s programs and portfolio strategy. Prior to Gate, Nina worked at Maze Therapeutics in small molecule drug discovery. Nina completed her postdoctoral training at Genentech and holds a Ph.D. from the MRC Laboratory of Molecular Biology, University of Cambridge. She has published several first-author papers in high-impact journals, including Nature. In her spare time, she enjoys off-the-beaten-path travel, discovering new cultures and cuisines, and reading literary fiction.

David Wyatt, Ph.D.

Director, Platform Sciences

Bio

David is Director and Head of Platform Science at Gate Bioscience. Prior to Gate, David worked at Maze Therapeutics, Element Genomics, and UCB Pharma developing technology platforms for drug discovery. David trained in Genetics and Molecular Biology at the University of North Carolina, where he studied DNA damage response polymerases while moonlighting as a semi-pro guitar player.

About us

Gate Bioscience

Leadership Team

Jordi Mata-Fink, Ph.D.

Pat Sharp, Ph.D.

Raman Talwar, M.S.

Brian Cathers, Ph.D.

Nina Oberbeck, Ph.D.

David Wyatt, Ph.D.

Board of Directors

Clare Ozawa, Ph.D.

Vineeta Agarwala, M.D., Ph.D.

Tom Daniel, M.D.

Scientific & Strategic Advisors

Scott Biller, Ph.D.

Jay Parrish, Ph.D.

James Winkler, Ph.D.

Rebecca Voorhees, M.Sc., Ph.D.

Ramanujan Hegde, M.D., Ph.D.

Ville Paavilainen, Ph.D.

Peter DiLaura

Our Investors

GATEBIO

Connect with us